How to Dose Transdermal Selegiline for Treatment-Resistant MDD?
Transdermal selegiline is a monoamine oxidase inhibitor (MAOI) used as a treatment option for patients with treatment-resistant major depressive disorder (MDD).
Why Transdermal Selegiline preferred over Oral Selegiline?
- Unlike oral selegiline, the transdermal patch bypasses the digestive system, reducing the risk of hypertensive crises related to dietary tyramine.
How to Dose Transdermal Selegiline for MDD?
- Starting Dose: 6 mg/24 hours
- Titrated up based on the patient’s clinical response, to a maximum of 12 mg/24 hours.
Role of Dietary Restrictions with Transdermal Selegiline:
- At doses below 9 mg/24 hours, dietary restrictions are generally not necessary, but for higher doses, patients should be advised to follow a low-tyramine diet.Â
This video is part of our first CME course on “Mastering Major Depressive Disorder Psychopharmacology“, offering 8.50 AMA PRA Category 1 Credits. If you’re a medical professional looking to enhance your knowledge with evidence-based, clinically relevant material, I encourage you to enroll in the course. It’s designed to provide practical insights for improving patient outcomes in everyday clinical practice.
CME ACADEMY #1
MASTERING
MAJOR DEPRESSIVE DISORDER
PSYCHOPHARMACOLOGY
TOTAL CREDITS: 8.50 AMA PRA CATEGORY 1 CREDITS
LEARNING OBJECTIVES:
- Evaluate the pharmacological mechanisms and clinical efficacy of various antidepressants used in treating Major Depressive Disorder (MDD).
- Apply evidence-based strategies to optimize antidepressant selection and dosing, tailored to individual patient profiles.Â
- Integrate adjunctive treatment options to enhance therapeutic outcomes in patients with treatment-resistant depression.
- Differentiate between various antidepressants in terms of their pharmacokinetics, efficacy, and side effect profiles.
© 2025 All Rights Reserved.
